Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Drug safety stories

Nov 16, 2026

FDA approves Roche's oral breast cancer pill Wilserdly

The FDA approved Roche's oral treatment for estrogen receptor-positive, HER2-negative advanced breast cancer, providing a new option for patients and a significant commercial boost for the Swiss drugmaker.

Nov 16, 2026·3 sources
00

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.

Nov 16, 2026·3 sources
00
Nov 9, 2026

FDA approves Bayer's asundexian as first-in-class factor XIa inhibitor for stroke prevention

The FDA approved asundexian (Sunharbo), a novel blood thinner from Bayer, to reduce the risk of recurrent stroke in adults, marking the first approval in the factor XIa inhibitor class.

Nov 9, 2026·6 sources
00

FDA requires GLP-1 drugmakers to add warning for rare eye condition

The FDA ordered makers of all GLP-1 medications, including Ozempic and Zepbound, to add label warnings about nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause permanent vision loss.

Nov 9, 2026·8 sources
00
Nov 6, 2026

Novartis links two tumor cases in children to Zolgensma gene therapy

Novartis disclosed that two of nine reported tumor cases in Zolgensma recipients showed evidence of the viral delivery vector integrating into patient DNA, raising new safety questions for the gene therapy field.

Nov 6, 2026·3 sources
00

FDA launches investigation into Novartis' Zolgensma over cancer cases

The FDA is investigating a 'serious risk' of cancer linked to Novartis' spinal muscular atrophy gene therapy Zolgensma, following reports of tumor cases in children. This follows Novartis linking two tumor cases in children to the therapy.

Nov 6, 2026·2 sources
00

Sarepta halts enrollment in confirmatory Phase 3 trial of Elevidys

Sarepta Therapeutics announced it will not enroll additional patients in the confirmatory Phase 3 trial of Elevidys, its Duchenne muscular dystrophy gene therapy, a study required to maintain the drug's accelerated approval.

Nov 6, 2026·2 sources
00
Nov 5, 2026

Novartis reports nine tumor cases possibly linked to Zolgensma gene therapy

Novartis confirmed that nine patients who received its spinal muscular atrophy gene therapy Zolgensma have developed tumors following treatment, with seven cases newly reported, raising serious safety concerns about the widely used pediatric drug.

Nov 5, 2026·3 sources
00
Oct 29, 2026

Study finds one in four users discontinue insomnia drug lemborexant due to side effects

Researchers from Rutgers and other universities analyzed hundreds of online reviews of lemborexant, a prescription insomnia medication, and found that approximately 25% of reviewers stopped or planned to stop taking the drug due to troubling side effects.

Oct 29, 2026·2 sources
00

Sutter Health review board improves access to anti-amyloid Alzheimer's therapies

Sutter Health has implemented a review board system to more efficiently process referrals for anti-amyloid therapies that slow Alzheimer's disease progression, as demand for these treatments increases. The approach aims to streamline access to these disease-modifying treatments for eligible patients.

Oct 29, 2026·2 sources
00
Oct 28, 2026

SAR402663 gene therapy shows 97% reduction in treatment burden for wet AMD in phase 2 trial

A phase 2 study presented in Vienna showed that SAR402663, a single intravitreal gene therapy injection for wet age-related macular degeneration, achieved a 97% reduction in treatment burden with positive efficacy and safety results. More than 90% of patients responded to the medium dose treatment.

Oct 28, 2026·2 sources
00
Oct 27, 2026

FDA warns Amgen over misleading Vectibix cancer drug promotional video

The US FDA warned Amgen that a promotional video for its colorectal cancer drug Vectibix was misleading because it highlighted benefits while failing to adequately disclose serious safety risks and patient limitations. The warning letter was issued on Tuesday.

Oct 27, 2026·2 sources
00

Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%

Artiva Biotherapeutics halted development of its experimental cell therapy for autoimmune conditions following two patient deaths in clinical trials and announced massive workforce reductions.

Oct 27, 2026·4 sources
00
Oct 23, 2026

Bristol Myers patient died after CAR-T treatment, company explains June trial pause

Bristol Myers Squibb disclosed that a multiple sclerosis patient died from septic pneumonia following zola-cel CAR-T treatment, linking prior adverse events to manufacturing reagent changes. The company plans to restart trials in early 2025.

Oct 23, 2026·5 sources
00
Oct 22, 2026

Rituximab linked to increased inflammatory bowel disease risk in multiple sclerosis patients

A study published in JAMA Neurology found that multiple sclerosis patients treated with rituximab have an increased risk of developing inflammatory bowel disease, particularly Crohn's disease, though the absolute risk remains low. The research compared rituximab to other MS treatments.

Oct 22, 2026·2 sources
00
Oct 14, 2026

Par Health issues nationwide recall of Argatroban injection due to particulate matter contamination

Par Health USA recalled 22 lots of Argatroban Injection 250 mg/2.5 mL after detecting particulate matter including cellulose, polystyrene, and possibly stainless steel in the product, posing risks of pulmonary emboli and organ damage.

Oct 14, 2026·2 sources
00
Oct 8, 2026

UK revokes marketing authorization for Valneva's IXCHIQ chikungunya vaccine

The UK Medicines and Healthcare products Regulatory Agency has revoked the marketing authorization for Valneva's IXCHIQ chikungunya vaccine following a benefit-risk assessment by the Commission on Human Medicines. The decision caused Valneva shares to fall on Monday.

Oct 8, 2026·3 sources
00
Sep 28, 2026

Inventia Healthcare recalls chlorthalidone blood pressure medication under FDA Class II risk level

Inventia Healthcare Limited is voluntarily recalling over 13,000 bottles of chlorthalidone tablets nationwide due to failures in critical dissolution testing. The FDA has classified this as a Class II recall, indicating the medication could cause temporary or medically reversible adverse health consequences.

Sep 28, 2026·4 sources
00
Sep 24, 2026

Merck's remigromig meets primary endpoint in diabetic macular edema trial amid safety concerns

Merck announced that remigromig, a tri-specific antibody acquired in a $1.3 billion buyout, achieved its primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for diabetic macular edema. However, language regarding the drug's safety profile has raised concerns among analysts.

Sep 24, 2026·4 sources
00
Sep 23, 2026

Oral menopausal hormone therapy linked to increased blood clot risk, Danish study finds

A nationwide Danish study found that oral menopausal hormone therapy is associated with elevated risk of venous thromboembolism regardless of dose, while high-dose oral forms also increased stroke and heart attack risk. Transdermal treatments showed no overall increase in thrombotic risk.

Sep 23, 2026·3 sources
00
Sep 22, 2026

Celldex barzolvolimab Phase 3 trials meet endpoints but report two anaphylaxis cases

Celldex Therapeutics' barzolvolimab achieved what analysts called best-in-class efficacy results in two Phase 3 trials for chronic spontaneous urticaria, meeting all primary and key secondary endpoints. However, the trials also reported two life-threatening anaphylaxis cases, causing shares to drop 13-15% despite the positive efficacy data.

Sep 22, 2026·6 sources
00
Sep 17, 2026

Xenon Pharmaceuticals pauses depression drug trials over neuropsychiatric side effects

Xenon Pharmaceuticals temporarily halted new patient enrollment in clinical studies of its experimental depression drug following reports of mental health-related adverse events, causing shares to fall.

Sep 17, 2026·3 sources
00
Sep 7, 2026

EMA investigates injectable iron medicines for severe bone complications

The European Medicines Agency has launched an investigation into injectable iron medicines after reports of severe hypophosphatemia leading to osteomalacia, including cases occurring after just one or two doses in patients without recognized risk factors.

Sep 7, 2026·1 source
00
Aug 24, 2026

FDA places clinical hold on Regenxbio gene therapy after MRI abnormalities

The FDA halted testing of Regenxbio's gene therapy for Hunter Syndrome after spinal MRI scans detected abnormalities in five trial participants. This is the second clinical hold placed on a Regenxbio gene therapy program.

Aug 24, 2026·2 sources
00
Aug 21, 2026

GOP lawmakers call on FDA to increase scrutiny of Chinese clinical trial data after gene therapy deaths

Two Republican members of the House of Representatives are urging the FDA to reject clinical data from China unless trial sites have been recently audited by the agency, following reports of three patient deaths in separate gene therapy clinical trials conducted in China.

Aug 21, 2026·2 sources
00
Aug 12, 2026

Prader-Willi syndrome experts raise safety concerns over Neurocrine's Vykat XR

Medical experts specializing in Prader-Willi syndrome flagged serious adverse events in patients taking Neurocrine Biosciences' drug Vykat XR, raising safety concerns about the treatment for the rare genetic disorder.

Aug 12, 2026·2 sources
00
Aug 6, 2026

Vistagen Reports Positive Safety and Efficacy Results for Fasedienol in Social Anxiety Disorder Study

Vistagen announced topline results from a repeat dose study of fasedienol for acute treatment of social anxiety disorder, showing favorable safety and tolerability profiles along with efficacy signals across primary and secondary endpoints in both repeat and single dose administrations.

Aug 6, 2026·1 source
00
Jul 30, 2026

India Takes Enforcement Action Against 90% of High-Risk Pharmaceutical Facilities in Nationwide Quality Drive

India's drug regulator has taken enforcement action against approximately 90% of inspected pharmaceutical facilities identified as high-risk under a nationwide quality initiative, as authorities intensify oversight amid increased global scrutiny of Indian-made drugs.

Jul 30, 2026·1 source
00
Jul 14, 2026

Study finds frailty risks with GLP-1 drugs in older adults

A large study found potential signs of frailty in older adults taking Eli Lilly's Zepbound may signal relatively high risks for adverse outcomes, raising concerns about GLP-1 obesity drug use in elderly populations.

Jul 14, 2026·1 source
00
Jul 10, 2026

EU Regulator Warns Desogestrel and Etonogestrel Contraceptives Carry Small Brain Tumor Risk

The European Medicines Agency safety committee announced that commonly used contraceptives containing desogestrel and etonogestrel carry a small increased risk of meningioma after prolonged use.

Jul 10, 2026·1 source
00
Jul 1, 2026

GLP-1 Weight Loss Drugs Face Legal and Safety Concerns as Medicare Coverage Expands to Seniors

Lawsuits over vision loss risks from Saxenda (liraglutide) emerge as Medicare begins covering GLP-1 medications for seniors over 65, raising questions about proper usage and safety in older populations.

Jul 1, 2026·2 sources
00
Jun 29, 2026

New England Journal of Medicine Retracts Amgen's Tavneos Clinical Trial Amid Data Manipulation Allegations

The New England Journal of Medicine retracted the main clinical trial used to approve Amgen's $500 million drug Tavneos, following allegations of data manipulation. The European Medicines Agency had previously recommended revoking the drug's approval over data integrity concerns.

Jun 29, 2026·1 source
00
Jun 4, 2026

ADC Therapeutics Blood Cancer Drug Trial Shows More Deaths Despite Meeting Primary Endpoint

ADC Therapeutics shares plunged 53% in premarket trading after a late-stage study of its blood cancer drug showed more deaths among treated patients, despite meeting its main goal. The safety signal represents a significant setback for the company's development program.

Jun 4, 2026·1 source
00
Apr 22, 2026

Roche Presents Multiple Sclerosis Drug Data Ahead of Regulatory Submission

Swiss drugmaker Roche presented latest clinical trial data for its experimental multiple sclerosis drug at a major conference, setting the stage for regulatory approval submissions, though safety questions remain under scrutiny.

Apr 22, 2026·1 source
00
Apr 18, 2026

Xanax Recalled Nationwide Over Failed Quality Specifications

A widely used anxiety medication (Xanax) is being pulled from shelves nationwide due to failed dissolution specifications, according to the FDA.

Apr 18, 2026·1 source
00

Top claims

  • ▪The FDA approved Roche Holding AG's oral breast cancer pill Wilserdly for patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer
  • ▪The approval of Wilserdly expands Roche Holding AG's footprint in an emerging class of medicines aimed at reshaping treatment for HR-positive breast cancer
  • ▪ESR1 gene mutations indicate that an estrogen receptor-positive breast tumor is developing resistance to standard therapies

Subtopics

Drug Policy, Pricing & Approval17Clinical trials14Drug Approval and Clinical Trials11Pharmaceutical Industry7Cancer & Oncology6Gene therapy6FDA regulation4Genetic diseases4Pharma4Post-market surveillance4Age related cognitive decline3Autoimmune disease treatments3Eli Lilly3GLP-1 medications3Zepbound3Anxiety2Clinical Trial Design & Evaluation2Drug labeling & regulation2European Union2FDA drug approval2GLP-1 drugs2Healthcare Access and Insurance2Lifestyle, Wellness and Nutrition2Obesity treatment2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories